STOCK TITAN
  1. Home
  2. News
  3. NRBO

NeuroBo Pharmaceuticals Inc - NRBO STOCK NEWS

Welcome to our dedicated news page for NeuroBo Pharmaceuticals (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on NeuroBo Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroBo Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroBo Pharmaceuticals's position in the market.

News
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Rhea-AI Summary
NeuroBo Pharmaceuticals dosed the first patient in its Phase 1 clinical trial evaluating DA-1726 for obesity treatment, with accelerated timelines for top-line data readout. The trial aims to assess safety, tolerability, and pharmacokinetics of DA-1726 in obese subjects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
clinical trial
-
News
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. completes enrollment of Part 1 of Phase 2a clinical trial for DA-1241, a GPR119 agonist for MASH treatment. Part 2 to explore combination therapy with sitagliptin. Full trial data expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
clinical trial
-
News
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. received IRB approval for Phase 1 trial of DA-1726 in Obesity and SRC approval for Phase 2a trial of DA-1241 for MASH. The company reported positive pre-clinical safety data for DA-1241 and expects data from Phase 2a trial in the second half of 2024. NeuroBo's cash position was $22.4 million as of December 31, 2023, expected to fund operations into the fourth quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
earnings
News
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. receives approval to continue Phase 2a clinical trial for DA-1241, a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH). The Safety Review Committee recommends trial continuation without modification after a positive safety review. Full data readout expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.21%
Tags
clinical trial
-
News
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. appoints Marshall Woodworth as CFO, highlighting his extensive experience in pharmaceutical and medical device companies. The company aims to leverage Woodworth's expertise in advancing clinical development of cardiometabolic assets, including DA-1241 and DA-1726, targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
management
-
News
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) receives IRB approval for Phase 1 trial of DA-1726, a novel cardiometabolic drug targeting obesity. First patient expected to be randomized in Q2 2024. Positive preclinical data suggests potential advantages over existing treatments. Top-line data expected in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.09%
Tags
clinical trial
News
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) announces participation in the BIO CEO & Investor Conference for one-on-one investor meetings and business development discussions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.65%
Tags
conferences
-
News
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. has announced the clearance of its Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist. Preclinical studies have shown that DA-1726 elicits superior weight loss compared to Semaglutide (Wegovy™) and similar weight loss compared to Tirzepatide (Mounjaro™), while consuming more food. The company plans to initiate a Phase 1 clinical trial for the treatment of obesity in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
67.28%
Tags
clinical trial
-
News
NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) announced positive pre-clinical safety data for DA-1241, a GPR119 agonist, in combination with sitagliptin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company has opened enrollment for Part 2 of its Phase 2a clinical trial and expects to report the full data readout in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
clinical trial
News
NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) has announced that it has regained compliance with Nasdaq's minimum bid price requirement and satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market, resulting in the closing of the listing matter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
none
Stock NRBO logo
NeuroBo Pharmaceuticals Inc

Nasdaq:NRBO

NRBO Rankings

#5253 Ranked by Market Cap
#5499 Ranked by Stock Gains
N/A Ranked by Dividends

NRBO Stock Data

17.71M
4.71M
61.67%
1.37%
1.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About NRBO

neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.